Compare Eni SpA (E) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Repligen Corporation Common Stock — how do they compare? Eni SpA trades at $57.41 (market cap $82.04B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Eni SpA is far larger — about 7.4× Repligen Corporation Common Stock's market cap, and Eni SpA pays a 4.25% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Repligen Corporation Common Stock for 0 Days on average.
| E | RGEN | |
|---|---|---|
Market Cap | $82.04B | $11.14B |
Volume | 245,093 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $57.71 | $194.57 |
52-Week Low | $34.20 | $102.87 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $106.48B | $11.02B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.71, up 1.66% today, with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 13.35 and P/S of 0.88, though recent earnings missed expectations in Q1 and Q2 2026. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, but net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic with 34.6% analyst buy ratings and improving profitability margins. Key opportunities include Venezuela oil expansion and cost discipline, while risks involve revenue volatility and execution challenges. The stock presents value characteristics with reasonable valuation, though investors should monitor earnings consistency and global energy market conditions.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
